Literature DB >> 22358377

[Value of positron emission tomography in urological neoplasms: more form than substance?].

J Müller1, M Schrader, A J Schrader, M Höpfner, F Zengerling.   

Abstract

Positron emission tomography/computed tomography (PET/CT) is widely used for imaging urological neoplasms. This overview should help the urologist actively involved in oncology to assess the value of PET or PET/CT in each tumor entity. Besides prostate, testicular, renal, and bladder cancer less common urological malignancies like penile carcinoma and retroperitoneal masses are discussed. Differences in using PET/CT for primary diagnosis, staging, or restaging are outlined separately. Appropriate indications for the use in clinical practice are cited.

Entities:  

Mesh：

Year:  2012        PMID： 22358377     DOI： 10.1007/s00120-012-2834-5

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  79 in total

1.  PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy.

Authors:  Giampiero Giovacchini; Maria Picchio; Vincenzo Scattoni; Rita Garcia Parra; Alberto Briganti; Luigi Gianolli; Francesco Montorsi; Cristina Messa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-20       Impact factor: 9.236

2.  18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients.

Authors:  Mohsen Beheshti; Larisa Imamovic; Gabriele Broinger; Reza Vali; Peter Waldenberger; Franz Stoiber; Michael Nader; Bernhard Gruy; Guenter Janetschek; Werner Langsteger
Journal:  Radiology       Date:  2010-03       Impact factor: 11.105

3.  18F-FDG PET/CT for staging of penile cancer.

Authors:  Bernhard Scher; Michael Seitz; Martin Reiser; Edwin Hungerhuber; Klaus Hahn; Reinhold Tiling; Peter Herzog; Maximilian Reiser; Peter Schneede; Stefan Dresel
Journal:  J Nucl Med       Date:  2005-09       Impact factor: 10.057

4.  11C-choline positron emission tomography in prostate cancer: primary staging and recurrent site staging.

Authors:  Soichiro Yoshida; Kazuaki Nakagomi; Shuichi Goto; Masami Futatsubashi; Tatsuo Torizuka
Journal:  Urol Int       Date:  2005       Impact factor: 2.089

5.  Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases.

Authors:  Tom Budiharto; Steven Joniau; Evelyne Lerut; Laura Van den Bergh; Felix Mottaghy; Christophe M Deroose; Raymond Oyen; Filip Ameye; Kris Bogaerts; Karin Haustermans; Hendrik Van Poppel
Journal:  Eur Urol       Date:  2011-01-18       Impact factor: 20.096

6.  131 I-cG250 monoclonal antibody immunoscintigraphy versus [18 F]FDG-PET imaging in patients with metastatic renal cell carcinoma: a comparative study.

Authors:  A H Brouwers; U Dorr; O Lang; O C Boerman; W J G Oyen; M G Steffens; E Oosterwijk; H G Mergenthaler; H Bihl; F H M Corstens
Journal:  Nucl Med Commun       Date:  2002-03       Impact factor: 1.690

7.  Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection.

Authors:  Axel Häcker; Stefan Jeschke; Karl Leeb; Kurt Prammer; Josef Ziegerhofer; Wolfgang Sega; Werner Langsteger; Guenter Janetschek
Journal:  J Urol       Date:  2006-11       Impact factor: 7.450

8.  [Positron emission tomography with [18 F]-2-fluoro-2-deoxy-D-glucose (18FDG-PET) in diagnosis of retroperitoneal lymph node metastases of testicular tumors].

Authors:  V Müller-Mattheis; M Reinhardt; C D Gerharz; G Fürst; H Vosberg; H W Müller-Gärtner; R Ackermann
Journal:  Urologe A       Date:  1998-11       Impact factor: 0.639

9.  Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study.

Authors:  Mohsen Beheshti; Reza Vali; Peter Waldenberger; Friedrich Fitz; Michael Nader; Wolfgang Loidl; Gabriele Broinger; Franz Stoiber; Ignac Foglman; Werner Langsteger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-09       Impact factor: 9.236

10.  Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography.

Authors:  David Lyrdal; Marianne Boijsen; Madis Suurküla; Sven Lundstam; Ulrika Stierner
Journal:  Nucl Med Commun       Date:  2009-07       Impact factor: 1.690
View more
  2 in total

1.  [Histopathology reports of findings of prostate needle biopsies. Individual treatment].

Authors:  I Damjanoski; J Müller; T J Schnöller; R Küfer; L Rinnab
Journal:  Urologe A       Date:  2013-02       Impact factor: 0.639

2.  Application of (18)F-FDG PET/CT imaging in diagnosing bladder tumor metastasis lesions.

Authors:  Yang Li; Zhong-Qing Yang; Hui Ye; Lin Qi; Jun-Wu Hu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-04-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.